Table 2.
Evaluation of the early treatment response after initiation of lenvatinib, grouped according to the dynamic CT enhancement pattern (Type-2-4) and analysis of imaging features using mRECIST
| Dynamic CT image of main target nodule type and number | Response evaluation using mRECIST, n (%) | |||
|---|---|---|---|---|
| Homogeneous enhancement pattern | ||||
| Type-2 (n = 15) | CR | PR | SD | PD |
| 1 (7%) | 7 (47%) | 6 (40%) | 1 (7%) | |
| ORR 53% |
||||
| Heterogeneous enhancement pattern | ||||
| Type-3 (n = 28) | CR | PR | SD | PD |
| 3 (11%) | 21 (75%) | 2 (7%) | 2 (7%) | |
| ORR 86% |
||||
| Type-4 (n = 13) | CR | PR | SD | PD |
| 2 (15%) | 9 (69%) | 1 (8%) | 1 (8%) | |
| ORR 85% |
||||
The composition ratio is rounded off to the first decimal place and therefore the total will not necessarily be 100. CR, complete response; CT, computed tomography; HU, Hounsfield units; mRECIST, Modified Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.